CG Oncology (CGON) Competitors

Viatris (NASDAQ:VTRS) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Is VTRS or CGON more profitable?

Viatris has a net margin of -24.57% compared to CG Oncology's net margin of -15,945.17%. Viatris' return on equity of 16.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-24.57%	16.54%	7.06%
CG Oncology	-15,945.17%	-19.37%	-18.72%

Do analysts prefer VTRS or CGON?

Viatris currently has a consensus price target of $10.40, suggesting a potential upside of 4.73%. CG Oncology has a consensus price target of $58.82, suggesting a potential upside of 37.27%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	3 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Which has higher valuation and earnings, VTRS or CGON?

CG Oncology has lower revenue, but higher earnings than Viatris. CG Oncology is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.74B	0.79	-$634.20M	-$2.90	-3.42
CG Oncology	$1.14M	2,866.06	-$88.04M	-$1.77	-24.21

Does the media favor VTRS or CGON?

In the previous week, CG Oncology had 11 more articles in the media than Viatris. MarketBeat recorded 14 mentions for CG Oncology and 3 mentions for Viatris. Viatris' average media sentiment score of 0.81 beat CG Oncology's score of 0.41 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders hold more shares of VTRS or CGON?

79.9% of Viatris shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more volatility & risk, VTRS or CGON?

Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, CG Oncology has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Summary

CG Oncology beats Viatris on 9 of the 17 factors compared between the two stocks.